Connect with us


Make in India: DoT may ask BSNL to try local end-to-end networks for 4G upgrade



The Department of Telecommunications (DoT) is mulling advising BSNL and MTNL to test out locally consolidated networks for a few months before they take a call on who to select to upgrade their 4G spectrum services, Hindustan Times has learnt.

The decision can have far-reaching ramifications as the new setup, if found feasible, can be replicated for other network providers and to upgrade to 5G services, the tender process for which is yet to begin.

HT has earlier reported that the DoT had set up a six-member panel to look into the 4G upgrade tender after it was scrapped on July 1. The decision had come in the wake of 20 Indian soldiers being killed in the Galwan Valley by China. The decision was also taken in keeping with the preference to Make in India policy of the telecom department, and a bid to reduce reliance on Chinese companies such as Huawei and ZTE.

The six-member panel, which has representatives from DoT, BSNL, MTNL and the industry, has already met five times and is in the final stage of outlining requirements for the fresh tender. The final tender requirements are likely to be concretised by the end of the week. The Rs 7,000-8,000 crore tender is part of the BSNL revival package that will allow it to expand its telecom presence.

“Indian manufacturers at present do not have a turn-key setup in place,” said a DoT official who did not wish to be named. “A turn-key setup offers end-to-end network, including both radio and core requirements that are consolidated at a central level by a single operator.”

According to the official, tech giants such as Nokia and Airtel have their own turn-key setups in India. The official that while seven companies manufacture radio equipment, used to set up towers, only two companies at present are capable of making core equipment, which translates the signals to provide telecom services.

“The core equipment is responsible for translating the signals that are carried by the radio equipment,” the official said. “The new approach likely incorporate multiple vendors to setup an end-to-end network.”

A member of the panel, on the condition of anonymity, told HT that reservations had been expressed about the ability of Indian tech companies to set up the network.

“We are discussing telling BSNL and MTNL to set up at least 10-20 towers using local equipment and connect it to the core,” said the member. “They can test if the equipment is giving appropriate results.”

According to experts, nearly 75% of the telecom equipment is sourced from companies outside India, especially the internal components. Two major Chinese firms with a stake in the Indian market are ZTE and Huawei, both Chinese companies. Other major players include Nokia, Ericsson and Samsung.

“We are not saying that Nokia or Airtel will not be able to provide services, but the idea is that the local manufacturers get a greater stake,” said the first official. “Nokia has an India-based office that employs many Indian engineers.”

At present, according to the preference to make in India policy of the DoT, those doing over 50% addition to product and network by using equipment made in India and not just assembled here given preference.

“If Tech Mahindra gives a bid for 112 and Nokia for 100, Tech Mahindra will be asked to match the bid,” said former DoT technical advisor RK Bhatnagar. “Ercisson’s value addition, for example, would be around 25%, making them eligible to be in preference category.”

Bhatnagar added that a version of the DoT’s proposal was discussed at a meeting convened by NITI Aayog in early July.

“Private players such as Tech Mahindra made a presentation that they have the capability,” said Bhatnagar. “They had asked for an opportunity, and NITI Aayog had suggested the same to DoT.”

“The players can be asked to set up a consolidated network, which will then be tested over 4 months to see if it’s a workable solution and then can be replicated in other places,” he added.


Brand Story

Zepto, 10-minute grocery delivery app, raises $100 million



Only five months subsequent to dispatching, 10-minute basic food item conveyance application Zepto on Tuesday reported it has raised $100 million driven by Y Combinator, taking its valuation to $570 million.

Other than the raise money, Zepto has been developing staggeringly rapidly and is significantly increasing its client base consistently.

In the course of recent months, Zepto has extended past Mumbai by dispatching in Bengaluru, Delhi, Gurgaon, Chennai, Hyderabad, and Pune (Kolkata to follow), the organization said in an assertion.

“Financial backers are reliably deciding to back Zepto due to our top tier execution. This is giving us extraordinary energy – we’re developing at an amazing rate, clients are adoring the item experience, our center unit financial matters are solid, and we have one of the most outstanding startup groups in India today,” said Aadit Palicha, Co-Founder and CEO.

The Series C raising money round saw support from new and existing financial backers, including Glade Brook, Nexus, Breyer Capital, Lachy Groom, Global Founders Capital, Contrary Capital, and that’s just the beginning.

The round came 45 days later the organization reported its $60 million raise money in November.

Conveying food in a short time is a game-changing encounter for clients in the nation, and a few players are presently joining the race.

“We are eager to twofold down and lead this round in Zepto. They initially dispatched with an alternate model, quickly turned to speedy trade in August 2021, and are presently adding 100,000 new clients consistently, 60% of the ladies,” said Anu Hariharan from Y Combinator.

Continue Reading


One stuck box of fertilizer shows the global supply chain crisis



Somewhere in the world’s busiest port of Shanghai, a container of fertilizer sits among tens of thousands of boxes, waiting for a ride to the U.S. It’s been on the dock for months, trapped by typhoons and Covid outbreaks that have worsened major congestion in the global supply-chain network.

While the fertilizer has been stranded there since May, the port is just one stop on the long journey from central China to the U.S. Midwest. Delays have stretched a delivery that ordinarily would take weeks to more than half a year. And that time frame will keep expanding, as the goods have barely started the roughly 15,000 kilometer (9,300 mile) trek.

This is the tale of one humble shipment and its arduous journey across the world. While some of the barriers keeping it from its final destination may be specific to this particular case, the journey is emblematic of the inertia that has gripped global trade during the pandemic.

From the U.S. to Sudan to China, container boxes have been lying at ports, railyards and in warehouses as the pandemic rages on. In an industry with 25 million containers and some 6,000 ships hauling them, it’s easy to see disruptions as one big headache confined to the shipping world. But each container that’s delayed is economic activity that’s restrained, heaping costs one box at a time on consumers and making it more challenging to put corn on consumers’ tables or deliver presents for the holidays.

It’s also a lesson in the ripple effects across global supply chains, showing the limits of diversification as all networks are still closely connected with China.

“All roads lead back to China, and that has a major effect across the entire supply chain,” said Dawn Tiura, head of U.S.-based Sourcing Industry Group. “Congestion at one port or factory has far-reaching implications for neighboring facilities, which trickles out across the world.”

Continue Reading


Bharat Biotech’s BBV154 leads global race for intranasal COVID-19 vaccine



Bharat Biotech’s nasal COVID-19 vaccine candidate BBV154 has become the front runner globally to likely commercialise an intranasal vaccine, following green signal from the government to conduct a combined Phase II and III final clinical trials in India. At present out of the 110 vaccines under clinical development globally, only eight are intranasal vaccines and three are oral vaccines. So far none of these vaccines have entered the final phase of trials and most are still in the first phase.

BBV154 is an intranasal replication-deficient chimpanzee adenovirus SARS-CoV-2 vectored vaccine, in-licensed from the Washington University in St Louis, USA. Nasal and oral vaccines are expected to be a game-changer second-generation COVID-19 vaccine, as they stimulate a broad immune response and prevent both infection and transmission. The non-invasive, needle-free vaccines do not require trained health care workers to administer the vaccine, have no risks of injuries and infections and is suited for children and adults. Unlike Covaxin, which is difficult to make, manufacturing can be scaled up fast and easily.  Compared to injectable vaccines, nasal and oral vaccines are expected to provide long-lasting protection.

Bharat Biotech is yet to announce its plans and timeline for the nasal vaccine’s future development.

Serum Institute of India and Codagenix have done a 48-subject Phase I clinical trial in the UK for an intranasal COVID-19 vaccine, COVI-VAC. This live attenuated candidate vaccine is expected to have potential to provide a broader immune response, in comparison to most COVID-19 vaccines that target only a portion of the virus. Codagenix has recently completed dosing for its Phase I trials and data is expected to come out in the third quarter of the year.

Nasdaq listed US biopharmaceutical company Altimmune, which was developing a three-dose intranasal vaccine candidate  AdCOVID, discontinued the project on July 29, as its first phase trials did not stimulate an adequate immune response in healthy volunteers. “The top-line Phase 1 clinical data are disappointing given the encouraging preclinical data and our substantial efforts in advancing a differentiated, intranasal vaccine candidate in the fight against COVID-19,” said Vipin K Garg, Altimmune’s India born President and Chief Executive Officer.

The University of Hong Kong, Xiamen University and Beijing Wantai Biological Pharmacy in China are trying a Phase II clinical trial of a two-dose influenza virus vector COVID-19 vaccine as an intranasal spray (DelNS1-2019-nCoV-RBD-OPT1). Its one year long second phase trial among 240 volunteers is going on and will conclude only by mid-December 2021.

The University of Oxford is conducting a single dose Phase I study of AstraZeneca’s ChAdOx1 nCOV-19 (Covishield in India and manufactured by the Serum Institute) to be administered intranasal among 54 volunteers in three groups. According to the trial design, the study started in April is estimated to complete the first phase only by February 2022.

Cuban government’s Center for Genetic Engineering and Biotechnology, which developed Latin America’s first COVID-19 vaccine Abdala, is undertaking a Phase I/II study of an intra-nasal three dose protein subunit vaccine candidate Mambisa (CIGB-669). According to the research agency, Mambisa is based on the formulation of the RBD (Receptor Binding Domain) protein and an immuno enhancer, Hepatitis B nucleocapsid antigen.

Canadian biotech Symvivo Corporation has ‘bacTRL-Spike’, as an oral capsule DNA vaccine candidate for the prevention of COVID-19, is undergoing Phase I trials in Australia. The trial was started only in November, last year. The global drug major Merck, known as MSD outside the United States and Canada, has taken exclusive license of Symvivo’s bacTRL platform of oral vaccines.  Symvivo has funding of about $4.57 million from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to develop this vaccine.

US biotech Meissa Vaccines’s MV-014-212, a single dose intranasal recombinant live attenuated COVID-19 vaccine, is undergoing Phase I trials and its interim trial data will come out by the end of this year. Another small US biotech, Vaxform and the US Specialty Formulations LLC (USSF) are developing an oral COVID-19 vaccine, which is also in its first phase. Similarly, another US small biotech CyanVac LLC is also attempting an intranasal parainfluenza virus based COVID-19 vaccine (CVXGA1), now in the first phase and its results are also expected only by the end of the year.

Mexican veterinary pharmaceutical company Laboratorio Avi-Mex is testing a live influenza virus based vaccine, both as an intranasal spray as well as an injection. It is starting Phase I trials and is funded by Mexico’s foreign ministry and the National Council of Science and Technology (Conacyt). The Mexican authorities hope to commercialise this vaccine by the end of the year.

Continue Reading


Enter your email address to get latest updates



Copyright © 2018 - 2022 Delhi Wire.